Enter a phrase above to search files and articles within the site.
Typically materials that are more than 5 years old will be archived
Displaying 1 - 7 of 7 results
Psoriatic Arthritis
https://www.niams.nih.gov/health-topics/psoriatic-arthritis
What is psoriatic arthritis? Psoriatic arthritis can occur in people who have psoriasis (scaly red and white skin patches). It affects the joints and areas where tissues attach to bone. The joints most often affected are: The outer joints of the fingers or toes. Wrists. Knees. Ankles. Lower back.
Psoriasis
https://www.niams.nih.gov/health-topics/psoriasis
What is psoriasis? Psoriasis is a chronic (long-lasting) disease in which the immune system works too much, causing patches of skin to become scaly and inflamed. Most often, psoriasis affects the: Scalp. Elbows. Knees. The symptoms of psoriasis can sometimes go through cycles, flaring for a few weeks or months followed by times when they subside (or go into remission). If you have psoriasis, you may have a higher risk of getting other serious conditions, including: Psoriatic arthritis. Heart attack or stroke. Mental health problems, such as low self-esteem, anxiety, and depression.
Rheumatoid Arthritis
https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic (long-lasting) disease that mostly affects joints, such as the wrist, hands, feet, spine, knees, and jaw. In joints, RA causes inflammation that leads to: Pain. Swelling Stiffness. Loss of function. Rheumatoid arthritis is an autoimmune disorder because the immune system attacks the healthy joint tissues. Normally, the immune system helps protect the body from infection and disease. RA may cause you to feel unusually tired, to have occasional fevers, and to have a loss of appetite. It also may cause other medical problems in the heart, lungs, blood, nerves, eyes
New rheumatoid arthritis drug targets NIH-discovered protein
https://www.niams.nih.gov/newsroom/press-releases/rheumatoid-arthritis-drug-targets-protein
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
New Insights Into How Psoriasis Arises and How It Heals
https://www.niams.nih.gov/newsroom/spotlight-on-research/new-insights-how-psoriasis-arises
Psoriasis is a chronic skin condition characterized by itchy red patches and silvery scales, usually on the elbows, knees or scalp. It affects about 2 percent of Americans, and is sometimes associated with other health problems, such as arthritis, diabetes and heart disease. The causes are not fully understood, but the condition is related to an abnormal immune assault on skin cells that triggers inflammation. Scientists have been trying to understand the molecular details of what causes psoriasis. Now, two studies funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and published in
Accelerating Medicines Partnership (AMP)
https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.